JP2016523969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523969A5 JP2016523969A5 JP2016525428A JP2016525428A JP2016523969A5 JP 2016523969 A5 JP2016523969 A5 JP 2016523969A5 JP 2016525428 A JP2016525428 A JP 2016525428A JP 2016525428 A JP2016525428 A JP 2016525428A JP 2016523969 A5 JP2016523969 A5 JP 2016523969A5
- Authority
- JP
- Japan
- Prior art keywords
- endothelin
- disease
- pharmaceutical composition
- receptor agonist
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940084139 Endothelin B receptor agonist Drugs 0.000 claims 9
- 239000003066 endothelin B receptor agonist Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 108010091477 IRL 1620 Proteins 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- NRTWVLDGYXCWHD-IGKRDWOESA-N 121204-87-3 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(C)C)C1=CN=CN1 NRTWVLDGYXCWHD-IGKRDWOESA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 108010092219 BQ 3020 Proteins 0.000 claims 1
- 208000004020 Brain Abscess Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 108010072844 Endothelin-3 Proteins 0.000 claims 1
- 102000007055 Endothelin-3 Human genes 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000009433 Moyamoya Disease Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- KBQLINQFUQUHIY-SGOWJZKMSA-N bq3020 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(C)=O)C(C)C)C1=CNC=N1 KBQLINQFUQUHIY-SGOWJZKMSA-N 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- LXPHPKVWHQLBBA-UHFFFAOYSA-N sarafotoxin s6c Chemical compound C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C1NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C2CSSCC(C(NC(CC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(CCSC)C(=O)NC(C(=O)NC(CC(O)=O)C(=O)NC(CCC(O)=O)C(=O)NC(CCC(O)=O)C(=O)N2)C(C)O)=O)NC(=O)C(C(C)O)NC(=O)C(N)CSSC1)CC1=CN=CN1 LXPHPKVWHQLBBA-UHFFFAOYSA-N 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020179020A JP7385924B2 (ja) | 2013-07-08 | 2020-10-26 | エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843702P | 2013-07-08 | 2013-07-08 | |
| US61/843,702 | 2013-07-08 | ||
| US201361902935P | 2013-11-12 | 2013-11-12 | |
| US61/902,935 | 2013-11-12 | ||
| PCT/US2014/045748 WO2015006324A2 (en) | 2013-07-08 | 2014-07-08 | Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020179020A Division JP7385924B2 (ja) | 2013-07-08 | 2020-10-26 | エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523969A JP2016523969A (ja) | 2016-08-12 |
| JP2016523969A5 true JP2016523969A5 (enExample) | 2017-08-10 |
| JP6928450B2 JP6928450B2 (ja) | 2021-09-01 |
Family
ID=52280704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525428A Active JP6928450B2 (ja) | 2013-07-08 | 2014-07-08 | エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法 |
| JP2020179020A Active JP7385924B2 (ja) | 2013-07-08 | 2020-10-26 | エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020179020A Active JP7385924B2 (ja) | 2013-07-08 | 2020-10-26 | エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10561704B2 (enExample) |
| EP (1) | EP3019242B1 (enExample) |
| JP (2) | JP6928450B2 (enExample) |
| CN (2) | CN105682741A (enExample) |
| AU (1) | AU2014287427B2 (enExample) |
| BR (1) | BR112016000431A8 (enExample) |
| CA (2) | CA2917325C (enExample) |
| ES (1) | ES2825101T3 (enExample) |
| PL (1) | PL3019242T3 (enExample) |
| WO (1) | WO2015006324A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010127096A2 (en) | 2009-04-30 | 2010-11-04 | Midwestern University | Novel therapeutic treatments using centhaquin |
| EP4364811A3 (en) * | 2018-05-03 | 2024-07-10 | Midwestern University | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
| US20240207356A1 (en) * | 2022-12-26 | 2024-06-27 | Pharmazz, Inc. | Composition and method for wound healing and repair of damaged nerves |
| WO2024222663A1 (zh) * | 2023-04-26 | 2024-10-31 | 拜西欧斯（北京）生物技术有限公司 | 多肽及其应用 |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954987A (en) | 1972-12-22 | 1976-05-04 | Sandoz, Inc. | 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock |
| US3983121A (en) | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| DE2557784C2 (de) | 1975-12-22 | 1986-04-17 | Hoechst Ag, 6230 Frankfurt | Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate |
| US4761417A (en) | 1982-05-14 | 1988-08-02 | Maroko Peter R | Compounds, compositions and method of treatments for improving circulatory performance |
| US5055470A (en) | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
| US5922681A (en) | 1992-09-14 | 1999-07-13 | Warner-Lambert Company | Endothelin antagonists |
| US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| SE0004455D0 (sv) * | 2000-12-01 | 2000-12-01 | Milos Pekny | Method for neuron regeneration in the central nervous system |
| AU2002241736A1 (en) | 2000-12-21 | 2002-07-01 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030232787A1 (en) | 2001-05-08 | 2003-12-18 | Dooley David James | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| WO2003009805A2 (en) * | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
| US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| JP2006508086A (ja) | 2002-10-24 | 2006-03-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 固形腫瘍を予防および治療するための方法および組成物 |
| CA2506850C (en) | 2002-11-20 | 2014-05-13 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
| JP2009530407A (ja) * | 2006-03-23 | 2009-08-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト |
| US8623823B2 (en) * | 2007-08-21 | 2014-01-07 | Midwestern University | Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist |
| CN101374259B (zh) * | 2007-08-22 | 2012-08-08 | 华为技术有限公司 | 实现多媒体彩铃和多媒体彩像业务的方法和装置 |
| KR101418941B1 (ko) | 2011-04-04 | 2014-07-15 | 서울대학교병원 | 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물 |
-
2014
- 2014-07-08 US US14/903,574 patent/US10561704B2/en active Active
- 2014-07-08 JP JP2016525428A patent/JP6928450B2/ja active Active
- 2014-07-08 CN CN201480049491.7A patent/CN105682741A/zh active Pending
- 2014-07-08 EP EP14823205.1A patent/EP3019242B1/en active Active
- 2014-07-08 CN CN202110467579.2A patent/CN113384701A/zh active Pending
- 2014-07-08 PL PL14823205T patent/PL3019242T3/pl unknown
- 2014-07-08 BR BR112016000431A patent/BR112016000431A8/pt not_active Application Discontinuation
- 2014-07-08 WO PCT/US2014/045748 patent/WO2015006324A2/en not_active Ceased
- 2014-07-08 AU AU2014287427A patent/AU2014287427B2/en active Active
- 2014-07-08 CA CA2917325A patent/CA2917325C/en active Active
- 2014-07-08 CA CA3171883A patent/CA3171883C/en active Active
- 2014-07-08 ES ES14823205T patent/ES2825101T3/es active Active
-
2019
- 2019-12-24 US US16/726,427 patent/US20200353031A1/en not_active Abandoned
-
2020
- 2020-10-26 JP JP2020179020A patent/JP7385924B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524822A5 (enExample) | ||
| JP2016523969A5 (enExample) | ||
| JP2016535786A5 (enExample) | ||
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| AR110747A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MA50800A (fr) | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson | |
| EP4306524A3 (en) | Lymphatic system-directing lipid prodrugs | |
| MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2016525095A5 (ja) | 環状ポリペプチド | |
| JP2016510326A5 (enExample) | ||
| ECSP19021843A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| WO2018071741A8 (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| JP2017505811A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| EP3248603A4 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
| JP2016537432A5 (enExample) | ||
| JP2017516835A5 (enExample) | ||
| EP4221704A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES | |
| JP2019500379A5 (enExample) | ||
| HRP20200161T1 (hr) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja | |
| EP3639859A4 (en) | ORAL MEDICINAL DELIVERY COMPOSITION WITH OXALIPLATIN AND MANUFACTURING METHOD FOR IT |